About Eukaryotic translation initiation factor 3 subunit M
Eukaryotic translation initiation factor 3 subunit M (EIF3M) is a protein
from Homo sapiens identified by UniProt accession
Q7L2H7, 374 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 3 subunit M |
| UniProt accession | Q7L2H7 |
| Gene | EIF3M |
| Organism | Homo sapiens |
| Length | 374 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (61)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.20
- age at menopause · score 0.16
- Agents acting on the renin-angiotensin system use measurement · score 0.13
- FEV/FVC ratio · score 0.13
- attention deficit hyperactivity disorder · score 0.09
- antisocial behaviour measurement · score 0.09
- substance abuse · score 0.09
- unipolar depression · score 0.09
- cystatin C measurement · score 0.09
- sex hormone-binding globulin measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q7L2H7-F1 | alphafold | PREDICTED | 55.28 | — |
Amino-acid sequence (374 residues)
MSVPAFIDIS EEDQAAELRA YLKSKGAEIS EENSEGGLHV DLAQIIEACD VCLKEDDKDV ESVMNSVVSL LLILEPDKQE ALIESLCEKL VKFREGERPS LRLQLLSNLF HGMDKNTPVR YTVYCSLIKV AASCGAIQYI PTELDQVRKW ISDWNLTTEK KHTLLRLLYE ALVDCKKSDA ASKVMVELLG SYTEDNASQA RVDAHRCIVR ALKDPNAFLF DHLLTLKPVK FLEGELIHDL LTIFVSAKLA SYVKFYQNNK DFIDSLGLLH EQNMAKMRLL TFMGMAVENK EISFDTMQQE LQIGADDVEA FVIDAVRTKM VYCKIDQTQR KVVVSHSTHR TFGKQQWQQL YDTLNAWKQN LNKVKNSLLS LSDT
Explore Eukaryotic translation initiation factor 3 subunit M with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets